AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application.

1-24. Cancelled

25. (Previously presented) A method for producing a pigment epithelial cell of the eye comprising an adenoviral vector, the method comprising introducing an adenoviral vector to the pigment epithelial cell of the eye and cultivating the cell in serum-free medium and in the presence of a feeder layer, the adenoviral vector comprising at least one expressed nucleic acid operatively linked to a promoter, said vector comprising neither adenoviral nor *E. coli* coding DNA sequences.

26 (New) The method as claimed in claim 25, wherein the pigment epithelial cell of the eye is a retinal pigment epithelial cell.

27. (New) The method as claimed in claim 25, wherein the nucleic acid expresses a protein selected from the group consisting of a neurotrophic factor, an antiangiogenic factor, an antioxidative factor, a lysosomal factor, and a vasodilating factor.

28. (New) The method as claimed in claim 27, wherein the protein is selected from the group consisting of GDNF, PEDF, NGF, BDNF, CNTF, bFGF, neurotrophin 3,4-5, a soluble VEGF receptor-1 (sflt-1), a dominant-negative VEGF receptor-2 (KDR), PEDF, superoxide dismutase, catalase, peroxidase, alpha-mannosidase, beta-galactosidase, N-acetyl-beta-glucosaminidase, N-acetyl-beta-galactosaminidase, lipase, and NO synthase.

29. (New) The method as claimed in claim 25, wherein the promoter is selected from the group consisting of a constitutively active promoter, a regulatable promoter, and a tissue-specific promoter.

30. (New) The method as claimed in claim 25, wherein the cell expresses at least one protein encoded by said expressed nucleic acid.

31. (New) The method as claimed in claim 25, wherein the cell expresses at least one RNA from said expressed nucleic acid.